Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target

Journal of Bacteriology

Volumn 194, Issue 3, 2012, Pages 663-668

  Ollinger, Juliane ^a   O'malley, Theresa ^a   Kesicki, Edward A ^a   Odingo, Joshua ^a   Parish, Tanya ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLDEPSIPEPTIDE; CLPP1 PROTEIN; CLPP2 PROTEIN; ENDOPEPTIDASE CLP; PROTEINASE; UNCLASSIFIED DRUG;

ANAEROBIC CELL CULTURE; ARTICLE; BACTERIUM CULTURE; CHROMOSOME DELETION; DRUG TARGETING; GENE OVEREXPRESSION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS;

BACTERIAL PROTEINS; ENDOPEPTIDASE CLP; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, BACTERIAL; MYCOBACTERIUM TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84855974368     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.06142-11     Document Type: Article

References (39)

1. Balganesh TS, Furr NJ. 2007. Molecular approaches to target discovery: evaluating targets for anti-tuberculosis drug discovery programmes. Infect. Disord. Drug Targets 7:120-126.
2. Barik S, Sureka K, Mukherjee K, Basu J, Kundu M. 2010. RseA, the SigE specific anti-sigma factor of Mycobacterium tuberculosis, is inactivated by phosphorylation-dependent ClpC1P2 proteolysis. Mol. Microbiol. 75: 592-606.
3. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43: 717-731.
4. Brötz-Oesterhelt H, et al. 2005. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 11:1082-1087.
5. Cheng L, et al. 2007. Discovery of antibacterial cyclic peptides that inhibit the ClpXP protease. Protein Sci. 16:1535-1542.
6. Cole ST, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
7. Duncan K. 2003. Progress in TB drug development and what is still needed. Tuberculosis 83:201-207.
8. Engels S, Schweitzer JE, Ludwig C, Bott M, Schaffer S. 2004. clpC and clpP1P2 gene expression in Corynebacterium glutamicum is controlled by a regulatory network involving the transcriptional regulators ClgR and HspR as well as the ECF sigma factor sigma(H). Mol. Microbiol. 52: 285-302.
9. Estorninho M, et al. 2010. ClgR regulation of chaperone and protease systems is essential for Mycobacterium tuberculosis parasitism of the macrophage. Microbiology 156:3445-3455.
10. Fedhila S, Msadek T, Nel P, Lereclus D. 2002. Distinct clpP genes control specific adaptive responses in Bacillus thuringiensis. J. Bacteriol. 184: 5554-5562.
11. Frees D, Qazi SNA, Hill PJ, Ingmer H. 2003. Alternative roles of ClpX and ClpP in Staphylococcus aureus stress tolerance and virulence. Mol. Microbiol. 48:1565-1578.
12. Gaillot O, Pellegrini E, Bregenholt S, Nair S, Berche P. 2000. The ClpP serine protease is essential for the intracellular parasitism and virulence of Listeria monocytogenes. Mol. Microbiol. 35:1286-1294.
13. Guo XV, et al. 2007. Silencing essential protein secretion in Mycobacterium smegmatis by using tetracycline repressors. J. Bacteriol. 189: 4614-4623.
14. Hinds J, et al. 1999. Enhanced gene replacement in mycobacteria. Microbiology 145:519-527.
15. Kar NP, Sikriwal D, Rath P, Choudhary RK, Batra JK. 2008. Mycobacterium tuberculosis ClpC1: characterization and role of the N-terminal domain in its function. FEBS J. 275:6149-6158.
16. Kovács K, Hurst LD, Papp B. 2009. Stochasticity in protein levels drives colinearity of gene order in metabolic operons of Escherichia coli. PLoS Biol. 7:e1000115.
17. Kress W, Maglica Z, Weber-Ban E. 2009. Clp chaperone-proteases: structure and function. Res. Microbiol. 160:618-628.
18. Kwon HY, et al. 2004. The ClpP protease of Streptococcus pneumoniae modulates virulence expression and protects against fatal pneumococcal challenge. Infect. Immun. 72:5646-5653.
19. Lee BG, et al. 2010. Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism. Nat. Struct. Mol. Biol. 17: 471-478.
20. Lee MH, Pascopella L, Jacobs WR, Hatfull GF. 1991. Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette- Guérin. Proc. Natl. Acad. Sci. U. S. A. 88:3111-3115.
21. Li DHS, et al. 2010. Acyldepsipeptide antibiotics induce the formation of a structured axial channel in ClpP: a model for the ClpX/ClpA-bound state of ClpP. Chem. Biol. 17:959-969.
22. Mahenthiralingam E, et al. 1998. Site-directed mutagenesis of the 19-kilodalton lipoprotein antigen reveals no essential role for the protein in the growth and virulence of Mycobacterium intracellulare. Infect. Immun. 66:3626-3634.
23. Milano A, et al. 2009. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis 89:84-90.
24. Muttucumaru DGN, Roberts G, Hinds J, Stabler RA, Parish T. 2004. Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis 84:239-246.
25. Parish T, Stoker NG. 2000. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology 146:1969-1975.
26. Pashley CA, Parish T. 2003. Efficient switching of mycobacteriophage L5-based integrating plasmids in Mycobacterium tuberculosis. FEMS Microbiol. Lett. 229:211-215.
27. Robertson GT, Ng WL, Foley J, Gilmour R, Winkler ME. 2002. Global transcriptional analysis of clpP mutations of type 2 Streptococcus pneumoniae and their effects on physiology and virulence. J. Bacteriol. 184: 3508-3520.
28. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48: 77-84.
29. Schmidt U, Lieberknecht A, Griesser H, Talbiersky J. 1982. Synthesis of peptide alkaloids. J. Org. Chem. 47:3261-3264.
30. Sherrid AM, Rustad TR, Cangelosi GA, Sherman DR. 2010. Characterization of a Clp protease gene regulator and the reaeration response in Mycobacterium tuberculosis. PLoS One 5:e11622.
31. Singh A, Mai D, Kumar A, Steyn AJC. 2006. Dissecting virulence pathways of Mycobacterium tuberculosis through protein-protein association. Proc. Natl. Acad. Sci. U. S. A. 103:11346-11351.
32. Socha AM, Tan NY, LaPlante KL, Sello JK. 2010. Diversity-oriented synthesis of cyclic acyldepsipeptides leads to the discovery of a potent antibacterial agent. Bioorg. Med. Chem. 18:7193-7202.
33. Wayne LG. 2001. In vitro model of hypoxically induced nonreplicating persistence of Mycobacterium tuberculosis. In Parish T, Stoker NG (ed), Mycobacterium tuberculosis protocols. Humana Press Inc, Totowa, NJ.
34. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
35. Wayne LG, Sohaskey CD. 2001. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55:139-163.
36. Weichart D, Querfurth N, Dreger M, Hengge-Aronis R. 2003. Global role for ClpP-containing proteases in stationary-phase adaptation of Escherichia coli. J. Bacteriol. 185:115-125.
37. WHO. 2010. Global tuberculosis control: WHO report 2010. World Health Organization, Geneva, Switzerland.
38. WHO. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland.
39. Williams KJ, Duncan K. 2007. Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr. Mol. Med. 7:297-307.